DK3149001T3 - Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere - Google Patents

Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere Download PDF

Info

Publication number
DK3149001T3
DK3149001T3 DK15733899.7T DK15733899T DK3149001T3 DK 3149001 T3 DK3149001 T3 DK 3149001T3 DK 15733899 T DK15733899 T DK 15733899T DK 3149001 T3 DK3149001 T3 DK 3149001T3
Authority
DK
Denmark
Prior art keywords
pyrazolopyrimidine derivatives
malt1 inhibitors
new
new pyrazolopyrimidine
malt1
Prior art date
Application number
DK15733899.7T
Other languages
English (en)
Inventor
Soldermann Carole Pissot
Jean Quancard
Achim Schlapbach
Oliver Simic
Marina Tintelnot-Blomley
Thomas Zoller
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3149001T3 publication Critical patent/DK3149001T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15733899.7T 2014-05-28 2015-05-27 Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere DK3149001T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170408 2014-05-28
PCT/IB2015/053975 WO2015181747A1 (en) 2014-05-28 2015-05-27 Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors

Publications (1)

Publication Number Publication Date
DK3149001T3 true DK3149001T3 (da) 2019-07-22

Family

ID=50828759

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15733899.7T DK3149001T3 (da) 2014-05-28 2015-05-27 Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere

Country Status (36)

Country Link
US (2) US9815842B2 (da)
EP (1) EP3149001B1 (da)
JP (1) JP6545197B2 (da)
KR (1) KR20170007311A (da)
CN (1) CN106170489B (da)
AP (1) AP2016009487A0 (da)
AR (1) AR100645A1 (da)
AU (1) AU2015265478B2 (da)
BR (1) BR112016024545A2 (da)
CA (1) CA2945077A1 (da)
CL (1) CL2016002942A1 (da)
CR (1) CR20160548A (da)
CU (1) CU24393B1 (da)
CY (1) CY1121946T1 (da)
DK (1) DK3149001T3 (da)
EA (1) EA032050B1 (da)
ES (1) ES2738695T3 (da)
GT (1) GT201600249A (da)
HR (1) HRP20191261T1 (da)
HU (1) HUE044351T2 (da)
IL (1) IL247949A0 (da)
LT (1) LT3149001T (da)
MX (1) MX373846B (da)
MY (1) MY182487A (da)
PE (1) PE20170189A1 (da)
PH (1) PH12016501862B1 (da)
PL (1) PL3149001T3 (da)
PT (1) PT3149001T (da)
RS (1) RS59039B1 (da)
SG (1) SG11201607895PA (da)
SI (1) SI3149001T1 (da)
SV (1) SV2016005328A (da)
TR (1) TR201910730T4 (da)
TW (1) TWI709561B (da)
UY (1) UY36143A (da)
WO (1) WO2015181747A1 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
EP3374361A1 (en) * 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107296807B (zh) * 2016-04-15 2020-03-20 中国科学院上海生命科学研究院 Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
EP3736277A1 (en) 2016-07-29 2020-11-11 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
EP3495348A4 (en) 2016-07-29 2020-01-22 Toray Industries, Inc. GUANIDINE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
WO2018020474A1 (en) * 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
US10689366B2 (en) 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3564228A4 (en) 2016-12-27 2020-08-12 Kao Corporation 1,3-DIOXANE-5-ONES MANUFACTURING PROCESS
WO2018124149A1 (ja) 2016-12-27 2018-07-05 花王株式会社 グリセリン酸エステルの製造方法
WO2018124148A1 (ja) * 2016-12-27 2018-07-05 花王株式会社 グリセリン酸エステルの製造方法
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
WO2018159650A1 (ja) * 2017-02-28 2018-09-07 東レ株式会社 グアニジン誘導体及びその医薬用途
EP3592731A4 (en) * 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES
WO2018226150A1 (en) * 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
US11117863B2 (en) 2017-06-08 2021-09-14 Mitsui Chemicals Agro, Inc. Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients
CN111433198A (zh) * 2017-11-17 2020-07-17 合帕吉恩治疗公司 作为ask1的抑制剂的脲衍生物
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
AU2019289223B2 (en) * 2018-06-18 2023-09-21 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EA202190055A1 (ru) 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
CN109503473B (zh) * 2019-01-07 2020-07-07 上海慧川生物医药科技有限公司 2-甲氧基-3-氨基-5-吡啶硼酸频哪醇酯及其中间体的合成方法
BR112021016400A2 (pt) 2019-02-22 2021-10-13 Janssen Pharmaceutica N.V. Forma cristalina de mono-hidrato de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil.)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
TW202115077A (zh) * 2019-07-01 2021-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｍａｌｔ１抑制劑及其用途
CN111138437B (zh) * 2019-12-04 2021-03-05 杭州华东医药集团新药研究院有限公司 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
EP4163280A4 (en) 2020-05-27 2024-06-05 Takeda Pharmaceutical Company Limited METHOD FOR PRODUCING A HETEROCYCLIC COMPOUND
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物
WO2022081967A1 (en) 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法
GB202018412D0 (en) 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
CN114805037B (zh) * 2021-01-29 2025-08-19 河北圣泰材料股份有限公司 1,2-二甲氧基-1,1,2,2-四氟乙烷的合成方法
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
JP2025503727A (ja) * 2022-01-18 2025-02-04 オーリジーン オンコロジー リミテッド Ｍａｌｔ－１阻害剤としての置換二環式複素環関連出願の相互参照 この出願は、２０２２年１月１８日に提出されたインド仮特許出願第２０２２４１００２８５９号に対する優先権を主張する。この仮出願の全内容は、参照により本明細書に組み込まれる。
CN116535424B (zh) * 2022-01-26 2025-04-11 武汉誉祥医药科技有限公司 作为malt1抑制剂的三并环化合物及其药物组合物和应用
TW202340198A (zh) * 2022-01-28 2023-10-16 大陸商上海齊魯製藥研究中心有限公司 靶向ｍａｌｔ１的蛋白降解化合物、包含其的醫藥組合物及其用途
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
CN119095837A (zh) 2022-02-03 2024-12-06 希四克斯探索有限公司 作为malt1抑制剂的杂环衍生物
EP4673150A2 (en) * 2023-03-01 2026-01-07 Rarefied Biosciences, Inc. Compositions and methods for treating malt1 associated diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
EP1545533A1 (en) 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP2397478A1 (en) * 2005-01-14 2011-12-21 CGI Pharmaceuticals, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity.
US20080176870A1 (en) * 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
EP2222326B2 (en) * 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL2509602T3 (pl) * 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
US9822118B2 (en) * 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用

Also Published As

Publication number Publication date
MX373846B (es) 2020-03-26
PL3149001T3 (pl) 2019-10-31
EP3149001A1 (en) 2017-04-05
US20180030061A1 (en) 2018-02-01
CU20160181A7 (es) 2017-05-10
EA032050B1 (ru) 2019-03-29
JP6545197B2 (ja) 2019-07-17
JP2017516778A (ja) 2017-06-22
GT201600249A (es) 2018-12-18
BR112016024545A2 (pt) 2017-08-15
UY36143A (es) 2016-01-08
CU24393B1 (es) 2019-04-04
IL247949A0 (en) 2016-11-30
AP2016009487A0 (en) 2016-10-31
LT3149001T (lt) 2019-08-12
CY1121946T1 (el) 2020-10-14
SV2016005328A (es) 2018-06-12
PH12016501862B1 (en) 2019-03-01
CL2016002942A1 (es) 2017-07-14
MX2016015544A (es) 2017-03-23
US10442808B2 (en) 2019-10-15
PT3149001T (pt) 2019-07-25
TW201609740A (zh) 2016-03-16
US20170121335A1 (en) 2017-05-04
US9815842B2 (en) 2017-11-14
ES2738695T3 (es) 2020-01-24
AR100645A1 (es) 2016-10-19
CR20160548A (es) 2017-01-02
CN106170489B (zh) 2019-05-03
HUE044351T2 (hu) 2019-10-28
MY182487A (en) 2021-01-25
RS59039B1 (sr) 2019-08-30
EP3149001B1 (en) 2019-04-24
PH12016501862A1 (en) 2016-12-19
PE20170189A1 (es) 2017-03-15
TR201910730T4 (tr) 2019-08-21
TWI709561B (zh) 2020-11-11
CN106170489A (zh) 2016-11-30
CA2945077A1 (en) 2015-12-03
HRP20191261T1 (hr) 2019-10-04
EA201692105A1 (ru) 2017-04-28
SI3149001T1 (sl) 2019-08-30
KR20170007311A (ko) 2017-01-18
AU2015265478B2 (en) 2017-09-14
WO2015181747A1 (en) 2015-12-03
SG11201607895PA (en) 2016-12-29
AU2015265478A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3233863T3 (da) Kondenserede ringheteroarylforbindelser og anvendelse deraf som trk-hæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
AP2016009487A0 (en) Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
DK3310784T3 (da) Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
DK3271349T3 (da) Benzimidazolederivater som bromodomain-inhibitorer
DK3143011T3 (da) Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
DK3341379T3 (da) EZH2-hæmmere
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3214079T3 (da) Seks-leddede benzodiazepinderivater som dpp-4-inhibitorer og hvordan de bruges
DK3347356T3 (da) Tricyclic forbundet pyridin-2-one-derivater og deres anvendelse som brd4-hæmmere
IL249674A0 (en) Quinolizinone derivatives as pi3k inhibitors
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
EP3454852A4 (en) PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS
DK3724196T3 (da) Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
DK3277682T3 (da) 6-morpholinyl-2-pyrazolyl-9h-purinderivater og anvendelse heraf som pi3k- hæmmere